Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy ...

In a bold move, the Chief Minister of Assam has announced that splitting the Dima Hasao district into two is under serious consideration. Conversation ...

Amplia Therapeutics Limited (OTCQB:INNMF ASX:ATX), based in Melbourne, Australia and focused on developing new therapies for hard to treat cancers, today ...

Boehringer Ingelheim has secured FDA approval for its PDE4 inhibitor nerandomilast (Jascayd) for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. Nerandomilast ...

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...

More than a decade after the last idiopathic pulmonary fibrosis (IPF) treatment gained U.S. FDA approval, Boehringer Ingelheim GmbH’s Jascayd (nerandomilast) is set to hit the market following the ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

The FDA has approved Boehringer Ingelheim’s twice-daily pill nerandomilast for the treatment of idiopathic pulmonary fibrosis. The drug will carry the brand name Jascayd. According to the FDA’s ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

Sept 24 (Reuters) - Britain's International Personal Finance (IPF.L), opens new tab said on Wednesday it received an increased 514.9 million pounds ($693.31 million) takeover proposal from U.S.-based ...

Fifty-five countries competed at the 2025 International Powerlifting Federation World Championships held in San Jose, Costa Rica, on Aug. 26-Sept. 5, and once again, St. Tammany Parish was well ...

A new research paper was published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled "AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging." In this ...